These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia. Böttcher M; Lentini S; Arens ER; Kaiser A; van der Mey D; Thuss U; Kubitza D; Wensing G Br J Clin Pharmacol; 2018 Jul; 84(7):1557-1565. PubMed ID: 29575006 [TBL] [Abstract][Full Text] [Related]
10. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors. Locatelli F; Minutolo R; De Nicola L; Del Vecchio L Drugs; 2022 Nov; 82(16):1565-1589. PubMed ID: 36350500 [TBL] [Abstract][Full Text] [Related]
11. Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease? Locatelli F; Del Vecchio L Nephrol Dial Transplant; 2020 Jun; 35(6):926-932. PubMed ID: 30844045 [TBL] [Abstract][Full Text] [Related]
12. Mutations in the gene encoding DMT1: clinical presentation and treatment. Iolascon A; De Falco L Semin Hematol; 2009 Oct; 46(4):358-70. PubMed ID: 19786204 [TBL] [Abstract][Full Text] [Related]
13. The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits. Zhou J; Li J; Rosenbaum DM; Zhuang J; Poon C; Qin P; Rivera K; Lepore J; Willette RN; Hu E; Barone FC PLoS One; 2017; 12(9):e0184049. PubMed ID: 28880966 [TBL] [Abstract][Full Text] [Related]
14. Altered expression of intestinal duodenal cytochrome b and divalent metal transporter 1 might be associated with cardio-renal anemia syndrome. Naito Y; Sawada H; Oboshi M; Okuno K; Yasumura S; Okuhara Y; Eguchi A; Nishimura K; Soyama Y; Asakura M; Ishihara M; Tsujino T; Masuyama T Heart Vessels; 2017 Nov; 32(11):1410-1414. PubMed ID: 28669019 [TBL] [Abstract][Full Text] [Related]
15. Iron handling and gene expression of the divalent metal transporter, DMT1, in the kidney of the anemic Belgrade (b) rat. Ferguson CJ; Wareing M; Delannoy M; Fenton R; McLarnon SJ; Ashton N; Cox AG; McMahon RF; Garrick LM; Green R; Smith CP; Riccardi D Kidney Int; 2003 Nov; 64(5):1755-64. PubMed ID: 14531808 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease. Sakashita M; Tanaka T; Nangaku M Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411 [TBL] [Abstract][Full Text] [Related]
17. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511 [TBL] [Abstract][Full Text] [Related]
18. Collagen Peptides as a Hypoxia-Inducible Factor-2α-Stabilizing Prolyl Hydroxylase Inhibitor to Stimulate Intestinal Iron Absorption by Upregulating Iron Transport Proteins. Zhu S; Wu L; Zhang M; Li S; Xing W; Zhao Z; Guo H; Ma L; Wu H J Agric Food Chem; 2022 Dec; 70(48):15095-15103. PubMed ID: 36475394 [TBL] [Abstract][Full Text] [Related]
19. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. Flamme I; Oehme F; Ellinghaus P; Jeske M; Keldenich J; Thuss U PLoS One; 2014; 9(11):e111838. PubMed ID: 25392999 [TBL] [Abstract][Full Text] [Related]
20. Haematopoietic effects of Angelica sinensis root cap polysaccharides against lisinopril-induced anaemia in albino rats. Younas F; Aslam B; Muhammad F; Mohsin M; Raza A; Faisal MN; Hassan SU; Majeed W Pharm Biol; 2017 Dec; 55(1):108-113. PubMed ID: 27925507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]